Table 3.
Demographics, medications, treatments, and diversity measures based on age group.
| Age 0 to <3 years (n = 12 study participants) | Age ≥3–6 years (n = 13 study participants) | Odds Ratio | P value | |
|---|---|---|---|---|
| Gender (n, % female)∗ | 7 (58) | 6 (46) | NA | 0.695 |
| Race (n, %)∗ | NA | 0.751 | ||
| White | 7 (58) | 6 (46) | ||
| Black | 1 (8) | 3 (23) | ||
| Other | 4 (33) | 4 (31) | ||
| Ethnicity (n, %)∗ | NA | >0.999 | ||
| Hispanic or Latino | 4 (33) | 4 (31) | ||
| Not Hispanic or Latino | 8 (67) | 9 (69) | ||
| CFTR Genotype (n, %) | NA | 0.683 | ||
| F508del homozygous | 5 (42) | 6 (46) | ||
| F508del heterozygous | 5 (42) | 3 (23) | ||
| Other | 2 (17) | 4 (31) | ||
| Inhaled antibiotics (n, % yes)∗ | 3 (25) | 2 (15) | NA | 0.645 |
| Antibiotics Courses in the 12 months Preceding Sample Collection (n, %)∗ | NA | 0.537 | ||
| None | 2 (17) | 0 (0) | ||
| 1–2 courses | 5 (42) | 5 (38.5) | ||
| 3–4 courses | 4 (33) | 5 (38.5) | ||
| 5 or more courses | 1 (8) | 3 (23) | ||
| CFTR modulator† (n, % yes) | 0 (0) | 5 (38) | NA | 0.039 |
| Age 0 to <3 years (n = 50 study samples) | Age ≥3–6 years (n = 59 study samples) | Odds Ratio¶ | P value | |
| Respiratory Culture (n, % yes)‡ | ||||
| Normal respiratory flora | 44 (88) | 40 (68) | 0.29 | 0.023 |
| Staphylococcus aureus | 2 (4) | 3 (5) | 1.29 | 0.802 |
| Pseudomonas aeruginosa | 2 (4) | 6 (10) | 2.72 | 0.217 |
| Other bacteria§ | 3 (6) | 11 (19) | 3.59 | 0.110 |
| Number of Sick Visits (n, % yes) | 7 (14) | 15 (25) | 2.09 | 0.191 |
| Oral Antibiotics (n, % yes) | 7 (14) | 13 (22) | 1.74 | 0.305 |
| IV Antibiotics (n, % yes) | 0 (0) | 1 (2) | NA | NA |
| Steroids (n, % yes) | 0 (0) | 4 (7) | NA | NA |
| Number of OTUs∗∗ (mean, standard error) | 63.9 (5.9) | 70.1 (5.6) | NA | 0.455 |
| Shannon Diversity Index∗∗(mean, standard error) | 2.15 (0.08) | 2.25 (0.08) | NA | 0.371 |
| Inverse Simpson Index∗∗ (mean, standard error) | 6.13 (0.41) | 6.52 (0.39) | NA | 0.482 |
| Morisita-Horn between subsequent encounters∗∗ (mean, standard error) | 0.78 (0.04) | 0.69 (0.04) | NA | 0.070 |
CFTR, cystic fibrosis transmembrane conductance regulator.
Fisher's exact test.
Ivacaftor n = 3, lumacaftor/ivacaftor n = 2.
Logistic regression, adjusting for repeated patient visits.
OR less than 1 more likely in Age 0 to <3 years, greater than 1 more likely in Age ≥3–6 years.
Other bacteria include Stenotrophomonas maltophilia (x5), Streptococcus pyogenes (x4), Streptococcus agalactiae (x3), Chryseobacterium species (x2), and Elizabethkingia meningoseptica.
Mixed effects generalized linear model, adjusting for repeated patient visits (p-value reported in the table) and whether the sample was collected at a sick or well visit (starting with OTUs, p-value was 0.223, 0.194, 0.334, and 0.028).